FY2026 Earnings Estimate for TWST Issued By William Blair

Twist Bioscience Co. (NASDAQ:TWST) – Stock analysts at William Blair issued their FY2026 earnings per share (EPS) estimates for shares of Twist Bioscience in a report released on Monday, November 18th. William Blair analyst M. Larew expects that the company will post earnings per share of ($1.50) for the year. The consensus estimate for Twist Bioscience’s current full-year earnings is ($3.13) per share.

A number of other research firms have also recently weighed in on TWST. Scotiabank raised their price objective on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research report on Tuesday. Leerink Partners lifted their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. lifted their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. Evercore ISI lifted their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Finally, Barclays lowered their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $51.78.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $41.32 on Wednesday. The stock has a market capitalization of $2.42 billion, a price-to-earnings ratio of -10.82 and a beta of 1.78. Twist Bioscience has a 1-year low of $23.00 and a 1-year high of $60.90. The business has a fifty day moving average price of $43.99 and a 200-day moving average price of $46.18.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. American International Group Inc. lifted its holdings in Twist Bioscience by 0.8% in the first quarter. American International Group Inc. now owns 28,506 shares of the company’s stock valued at $978,000 after acquiring an additional 213 shares during the last quarter. Caprock Group LLC lifted its holdings in Twist Bioscience by 2.9% in the second quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock valued at $387,000 after acquiring an additional 220 shares during the last quarter. Signaturefd LLC lifted its holdings in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after acquiring an additional 306 shares during the last quarter. Arizona State Retirement System lifted its holdings in Twist Bioscience by 1.9% in the second quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock valued at $798,000 after acquiring an additional 308 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in Twist Bioscience by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock valued at $457,000 after acquiring an additional 312 shares during the last quarter.

Insider Activity at Twist Bioscience

In other news, CEO Emily M. Leproust sold 1,730 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $46.94, for a total transaction of $81,206.20. Following the transaction, the chief executive officer now directly owns 495,523 shares in the company, valued at $23,259,849.62. The trade was a 0.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Dennis Cho sold 659 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $41.56, for a total value of $27,388.04. Following the transaction, the insider now owns 94,481 shares in the company, valued at approximately $3,926,630.36. This represents a 0.69 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,118 shares of company stock worth $4,391,151 in the last 90 days. Corporate insiders own 3.92% of the company’s stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.